These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9510983)

  • 1. Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens.
    Eppler S; Senn T; Gilkerson E; Modi NB
    Biopharm Drug Dispos; 1998 Jan; 19(1):31-8. PubMed ID: 9510983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
    J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative time course of thrombolysis induced by intravenous boluses and infusion of staphylokinase and tissue plasminogen activator in a rabbit arterial thrombosis model.
    Helft G; Bara L; Bloch MF; Samama MM
    Blood Coagul Fibrinolysis; 1998 Jul; 9(5):411-7. PubMed ID: 9712289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective.
    Martin U; Kaufmann B; Neugebauer G
    Clin Pharmacokinet; 1999 Apr; 36(4):265-76. PubMed ID: 10320949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.
    Modi NB; Fox NL; Clow FW; Tanswell P; Cannon CP; Van de Werf F; Braunwald E
    J Clin Pharmacol; 2000 May; 40(5):508-15. PubMed ID: 10806604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator.
    van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF
    Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction.
    Koster RW; Cohen AF; Kluft C; Kasper FJ; van der Wouw PA; Weatherley BC
    Clin Pharmacol Ther; 1991 Sep; 50(3):267-77. PubMed ID: 1914361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Tebbe U; Tanswell P; Seifried E; Feuerer W; Scholz KH; Herrmann KS
    Am J Cardiol; 1989 Sep; 64(8):448-53. PubMed ID: 2505604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase.
    Larsen GR; Timony GA; Horgan PG; Barone KM; Henson KS; Angus LB; Stoudemire JB
    J Biol Chem; 1991 May; 266(13):8156-61. PubMed ID: 1708773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.
    Kostis JB; Dockens RC; Thadani U; Bethala V; Pepine C; Leimbach W; Vachharajani N; Raymond RH; Stouffer BC; Tay LK; Shyu WC; Liao WC
    Clin Pharmacokinet; 2002; 41(6):445-52. PubMed ID: 12074692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction.
    Seifried E; Tanswell P; Ellbrück D; Haerer W; Schmidt A
    Thromb Haemost; 1989 Jun; 61(3):497-501. PubMed ID: 2508258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular biology of plasminogen activators: what are the clinical implications of drug design?
    Smalling RW
    Am J Cardiol; 1996 Dec; 78(12A):2-7. PubMed ID: 8990404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of staphylokinase and alteplase in rabbit bleeding time models.
    Vanderschueren S; Collen D
    Thromb Haemost; 1996 May; 75(5):816-9. PubMed ID: 8725729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
    Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jul; 346(1):108-13. PubMed ID: 1407000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction.
    Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators
    N Engl J Med; 1997 Oct; 337(16):1124-30. PubMed ID: 9340504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.
    Goldhaber SZ; Agnelli G; Levine MN
    Chest; 1994 Sep; 106(3):718-24. PubMed ID: 8082347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.